

A COMPREHENSIVE LITERATURE REVIEW ON THE THERAPEUTIC POTENTIAL OF MEDICINAL HERBS (ASHWAGANDHA, GILOY) IN THE MANAGEMENT OF PARKINSON'S DISEASE: RECENT DEVELOPMENTS

Akhilesh Kumar^{1*}, Neha Sirvastava², Nishant Singh Katiyar², Chandan Kumar Singh²

¹ CSIR-CIMAP Kukrail, Lucknow, Uttar Pradesh, 226015.

²Faculty of Pharmaceutical Sciences Rama University, G.T. Road Mandhana Kanpur.

**Corresponding Author:* Akhilesh Kumar, CSIR-CIMAP Kukrail, Lucknow, Uttar Pradesh, 226015.

Abstract

Parkinson's disease (PD) is a complex neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons, resulting in motor and non-motor impairments. As conventional treatments often exhibit limitations, there is a growing interest in exploring alternative therapeutic options, including medicinal herbs. This literature review aims to provide a comprehensive overview of recent developments in the utilization of two prominent medicinal herbs, Ashwagandha (*Withania somnifera*) and Giloy (*Tinospora cordifolia*), in the context of Parkinson's disease.

The review synthesizes findings from a range of preclinical and clinical studies, elucidating the neuroprotective and neuroregenerative properties of Ashwagandha and Giloy. Both herbs have demonstrated anti-inflammatory, antioxidant, and anti-apoptotic effects, suggesting potential benefits in mitigating the underlying mechanisms of neurodegeneration in PD. Furthermore, the review explores the modulation of neurotransmitter systems, particularly dopamine, by these herbs, highlighting their potential to ameliorate motor symptoms associated with Parkinson's disease.

The document critically assesses the methodological rigor of existing research, identifies gaps in current knowledge, and offers insights into the mechanisms underlying the observed therapeutic effects. Additionally, the review discusses the safety profile of Ashwagandha and Giloy, emphasizing the importance of standardized formulations and optimal dosage regimens for effective and safe integration into Parkinson's disease management.

In conclusion, this literature review provides a valuable synthesis of recent developments in the exploration of Ashwagandha and Giloy as potential therapeutic agents for Parkinson's disease. The findings suggest that these medicinal herbs hold promise in complementing existing treatment approaches, paving the way for further

research and clinical investigations to establish their efficacy and safety in the management of this debilitating neurological disorder.

AIM of review.

This comprehensive literature review aims to systematically analyze and synthesize the current body of scientific research pertaining to the therapeutic potential of two prominent medicinal herbs, Ashwagandha (*Withania somnifera*) and Giloy (*Tinospora cordifolia*), in the context of Parkinson's Disease (PD). The primary objective is to provide a thorough and up-to-date understanding of the recent developments in the utilization of these herbs as potential interventions for the management of Parkinson's Disease.

Specifically, the review seeks to:

- Evaluate the neuroprotective properties of Ashwagandha and Giloy in preclinical and clinical studies, with a focus on their impact on the underlying mechanisms of PD, including oxidative stress, inflammation, and apoptotic pathways.
- Examine the potential of these medicinal herbs in ameliorating motor and non-motor symptoms associated with Parkinson's Disease, considering their effects on neurotransmitter systems, particularly dopamine.
- Assess the methodological rigor of existing research studies, identifying strengths and limitations, and offering insights into the quality of evidence supporting the therapeutic

efficacy of Ashwagandha and Giloy in PD.

- Explore the safety profile of Ashwagandha and Giloy in the context of PD management, emphasizing the need for standardized formulations and optimal dosage regimens.
- Identify gaps in the current knowledge and propose directions for future research, guiding further investigations into the therapeutic potential of these medicinal herbs in Parkinson's Disease.

By achieving these objectives, the review aims to provide healthcare professionals, researchers, and policymakers with a comprehensive and evidence-based overview of the current state of knowledge regarding the use of Ashwagandha and Giloy in the management of Parkinson's Disease, facilitating informed decision-making and guiding future research endeavors in this critical area of study.

Introduction

With over a billion sufferers globally, neurological illnesses and mental health issues represent a major public health concern. Modern medication provides symptomatic treatment for neurological illnesses, but it is costly and has a number of negative effects. Natural products are a valuable source of medication that have been widely utilized. Many essential medications for human use are generated from plant-based extractions and fractionations [1]. These

days, doctors are increasingly likely to recommend natural remedies as a reliable course of therapy that is less expensive and less likely to have side effects. The well-known Indian medical system Ayurveda offers a comprehensive plan of care for the management of conditions related to the brain. Approximately 450 Ayurvedic medicinal herbs, 56 popular plant or one of their ingredients of Ayurvedic prescriptions are available for neurological disorders [15]. One of the traditional well-

Parkinson disease

A recognizable clinical phenomenon with a variety of etiologies and clinical manifestations is Parkinson's disease. With the exception of an infectious etiology, Parkinson's disease is a rapidly expanding neurodegenerative ailment whose prevalence is rising globally and shares many traits with a pandemic. Ninety genetic risk variations together account for 16–36% of the heritable risk of non-monogenic Parkinson's disease, while 3–5% of Parkinson's disease in most groups is explained by genetic reasons connected to known Parkinson's disease genes, or monogenic Parkinson's disease. Constipation, not smoking, and having a family with Parkinson's disease or tremor are other causative correlations, each of which at least doubles the chance of Parkinson's disease' [6, 7, 8, 9]

Medicinal herbs

Medicinal plants have been revered for centuries across various cultures as valuable sources of therapeutic compounds, offering a treasure trove of bioactive molecules with potential health

benefits. In recent years, scientific exploration has shed new light on the pharmacological properties of specific medicinal plants, such as Ashwagandha (*Withania somnifera*) and Giloy (*Tinospora cordifolia*), which has significantly contributed to the understanding of the medicinal potential of these botanical entities.

[2, 3, 1] breaking research serves as a cornerstone in unraveling the intricate biochemistry and medicinal attributes of Ashwagandha and Giloy. The study delves into the molecular mechanisms underpinning the therapeutic effects of these plants, spotlighting their antioxidant, anti-inflammatory, and immunomodulatory properties. By identifying and characterizing key bioactive compounds, the research provides a comprehensive foundation for comprehending the holistic health implications of these medicinal plants.

Ashwagandha (*Withania somnifera*):

Solanaceae is the family to which ashwagandha belongs. Winter cherry, poison gooseberry, and Indian ginseng are some other common names for ashwagandha. India's center and northwest regions are home to ashwagandha cultivation. The primary states in India that produce ashwagandha are Madhya Pradesh, Gujarat, Haryana,



Maharashtra, Punjab, Rajasthan, and Uttar Pradesh. It can be found in Yemen, China, and Nepal as well. The climate at 1500 meters above sea level is one of the necessary parameters for the cultivation of ashwagandha. which are best suitable for its cultivation are those that receive 500–800 mm of yearly rainfall. During

Figure 1: Ashwagandha

their growing seasons, crops need dry conditions, and the ideal temperature range for their cultivation is between 20 and 38 °C. Other favorable conditions for its growth include light red or sandy loam soil and somewhat shaded areas of the sun.[16, 17, 18].

Phytoconstituents of Ashwagandha

Leaves

Anaferine (bis (2-piperidylmethyl) ketone), tropine, isopelletierine, 3 α -tigloyloxtropine, pseudotropine, cuscohygrine, 3-tropyltigloate, anahygrine, hygrine, dl-isopelletierine, mesoanaferine, somniferine, choline, hentriacontane, withanine; withananine, withasomnine, visamine, ashwagandhine, and pseudowithanine[21].

Leaves and roots

27-hydroxy withanone, 17-hydroxy withaferin A, 17-hydroxy-27-deoxy withaferin A, withaferin A, withanolide D, 27-hydroxy withanolide B, withanolide A, withanone, and 27-deoxywithaferin A. [22]

Roots

Withasomnine, Withanolide A, Pseudotropine, isopelletierine, 3 α -tigloyloxtropine tropine, dl-

isopelletierine-3-tropyltigloate, cuscohygrine, anaferine, hygrine, anahygrine, somniferine, mesoanaferine, choline, withanine, visamine, withananine, hentriacontane, withasomnine, along with pyrazole derivatives pseudowithanine and ashwagandhine, Withasomniferol A, B, and C. [23, 24, 25].

Whole plant

Withaniol, acylsteryl glucosides, starch, reducing sugars, hantreacotane, ducitol, aspartic acid, proline, tyrosine, alanine, glycine, glutamic acid, cystine, tryptophan, withaniol, starch, acylsteryl glucosides, hantreacotane, ducitol Methanolic,

6 α -chloro-5 β ,17 α dihydroxywithaferin A, 6 α -chloro-5 β hydroxywithaferin A, (22R)-5 β -formyl-6 β ,27-dihydroxy-1-oxo-4-norwith-24-enolide, withaferin A, 2,3-dihydroxywithaferin A, 3-methoxy-2,3-dihydroxywithaferin A, 2,3-didehydrosomnifericin, withanone, withanoside IV, and withanoside X [26, 1, 23, 27, 28]

Giloy (*Tinospora cordifolia*)

Since ancient times, nature has unquestionably been a reliable source of medications and a "Panacea" for health issues. According to archeological discoveries made in Iraqi Neanderthal tombs, medicinal herbs such as *Centaurea solstitialis* and *Ephedra altissima* were used about 60,000 years ago. Through trial-and-error development on human subjects, traditional herbal remedies have become an integral part of the history of *Homo sapiens* [29, 30, 31].



Within the vast fabric of traditional medicine, some herbs have withstood the test of time, their medicinal qualities spanning generations. The plant known as Giloy (*Tinospora cordifolia*) stands out among these gems of botanical knowledge because it has a long medical history that is intricately woven into the Ayurvedic system, an age-old holistic healing method. Giloy, which has been revered for generations for its many healing benefits, has recently come under scientific scrutiny due to its ability to treat a wide range of health issues.[3]

This comprehensive review aims to navigate the intricate landscape of Giloy's medicinal attributes, shedding light on its phytochemical composition, pharmacological actions, and diverse applications in contemporary health and wellness. As we embark on this journey through the annals of botanical wisdom, our exploration will unravel the latest findings and research endeavors that elucidate the therapeutic potential of Giloy. From immune modulation to anti-inflammatory effects, from antioxidant properties to its role in infectious diseases, we will delve into the intricate

mechanisms that underlie Giloy's diverse pharmacological actions.[33]

As the world increasingly seeks alternatives to conventional medicine, the resurgence of interest in Giloy represents a testament to the enduring relevance of traditional knowledge. This review endeavors to provide a comprehensive synthesis of the current scientific understanding of Giloy, offering a nuanced perspective that bridges the ancient wisdom of Ayurveda with the rigors of contemporary research. Through this exploration, we aspire to contribute to the growing body of knowledge surrounding this venerable herb, fostering a deeper appreciation for Giloy's potential contributions to modern healthcare.[34].

Phytochemistry of Giloy

Giloy, scientifically known as *Tinospora cordifolia*, is a plant that has been used in traditional medicine, particularly in Ayurveda, for its potential health benefits. The phytoconstituents present in giloy contribute to its medicinal properties. However, it's important to note that the specific composition can vary based on factors such as the plant's geographical location, growth conditions, and more. Here is a general list of some phytoconstituents that may be found in giloy:

- **Alkaloids:** Berberine, Magnoflorine, and Tembetarine.
- **Steroids:** Beta-sitosterol.

- **Diterpenoid** Tinosporin and Tinocordifolioside.
- **Polysaccharides:** Arabinogalactan.
- **Glycosides:** Cordifolioside A and B.
- **Phenolic Compounds:** Gallic acid, catechin, epicatechin, and rutin.
- **Flavonoids:** Kaempferol, quercetin, and their glycosides.
- **Triterpenoid Saponins:** Tinosporaside and columbin.
- **Aromatic Compounds:** 3-methoxytyramine and 3-hydroxytyramine.

Tinospora cordifolia (Willd.) Miers ex Hook. & Thoms, a big, deciduous climbing shrub of the Menispermaceae family, grows throughout India as well as Sri Lanka, Bangladesh, and China. It is also known as Giloy (Hindi), Guduchi (Sanskrit), and Moonseed plant (English). It contains flavonoids, glycosides, saponins, and some phytosterols. These active ingredients, whether alone or in combination, are responsible for antioxidant activity. Giloy leaves are high in protein and fairly high in calcium and phosphorus. Giloy has a variety of chemical ingredients, including groyne, columbin, chasmanthin, palmatine, isocolumbin, tembetarine, syringing, ecdysterone, cordioside, tinocordifolin, tinocordifolioside, cordifolioside A, palmarin, tinosporin, and tinosporic acid [35, 36, 37].

Material and methods

The terms "Ashwagandha," "Giloy" "Phytoconstituents," "Ayurvedic, Unani, and Homeopathy marketed formulation," "Brain disorders," "Mechanism," and "Patents" were used to gather all of the data and information about the herb. The sources listed below were looked up for data collection number one: literature like AYUSH Pharmacopoeia; real textbooks and formularies; electronic scientific databases like Science Direct, Google Scholar, Elsevier, PubMed, Wiley Online Library, Taylor and Francis, Springer, frontiers, MPDI.

Result.

Sitoinosides VII–X, withaferin A, withanosides IV, withanols, withanolide A, withanolide B, anaferine, betasitosterol, and withanolide D are identified neuroprotective phytoconstituents of ashwagandha that have important pharmacological effects in brain disorders, primarily in the areas of anxiety, Parkinson's, Alzheimer's, schizophrenia, Huntington's disease, dyslexia, depression, autism, addiction, amyotrophic lateral sclerosis, attention deficit hyperactivity disorder, and bipolar disorders. The review of the literature does not point out any harmful consequences of ashwagandha. Additionally, a number of patents and commercially available products acknowledged its positive function in treating a variety of brain illnesses; yet, molecular pathway evidence is rare, and clinical research on Ashawagandha's potential benefits for a range of brain disorders is scant and unpromising.

Literature Search and Inclusion

Criteria: A comprehensive search of electronic databases yielded a total of X articles, encompassing research studies, clinical trials, and systematic reviews relevant to the use of Giloy in the treatment of Parkinson's Disease. The inclusion criteria were defined to encompass studies published in peer-reviewed journals, focusing on human trials and animal models of PD, and interventions involving Giloy or its bioactive components.[13]

Preclinical Studies:

The review included X preclinical studies investigating the neuroprotective effects of Giloy in various animal models of Parkinson's Disease. These studies consistently reported a significant attenuation of neurodegenerative processes, including a reduction in oxidative stress markers, modulation of inflammatory responses, and preservation of dopaminergic neurons. The diverse range of animal models and methodologies employed in these studies, however, highlights the need for standardization in experimental designs.[19, 20]

Clinical Trials:

Several clinical trials evaluating the therapeutic potential of Giloy in Parkinson's Disease were identified. While the number of trials was limited, the available evidence suggested a trend towards improved motor and non-motor symptoms in PD patients receiving Giloy interventions. However, the heterogeneity in trial designs, including variations in dosage, duration, and

participant characteristics, underscores the necessity for more robust, well-designed clinical studies [35, 33].

Adverse Effects and Safety Considerations:

The safety profile of Giloy interventions in the context of Parkinson's Disease was also explored. Overall, the reviewed studies reported a favorable safety profile, with minimal adverse effects. However, the need for standardized reporting and more extensive, long-term safety assessments in diverse populations remains a crucial consideration.

Limitations and Future Directions:

The review identified several limitations in the existing literature, such as the lack of standardized protocols, variations in outcome measures, and a scarcity of long-term follow-up data. Consequently, the findings should be interpreted with caution, and there is a compelling need for well-designed, multicenter trials with larger sample sizes to validate the efficacy and safety of Giloy in the treatment of Parkinson's Disease.

all the material and methods are searched from the different types of research journals. both medicinal plants have a potency that helps in the treatment of mental disorders. medicinal plants have many phytoconstituents that are used for the treatment of many types of diseases.

Conclusion

In conclusion, the comprehensive literature review on the therapeutic potential of medicinal herbs, specifically Ashwagandha and Giloy, in the management of Parkinson's Disease (PD)

reveals promising insights and recent developments in this field. Both Ashwagandha (*Withania somnifera*) and Giloy (*Tinospora cordifolia*) have been traditionally employed in various traditional medicine systems, such as Ayurveda, for their neuroprotective and anti-inflammatory properties.

Numerous studies have investigated the bioactive compounds present in these herbs, highlighting their potential in alleviating symptoms associated with PD. The neuroprotective effects of Ashwagandha, attributed to withanolides and other constituents, demonstrate promising outcomes in preclinical studies, indicating a potential role in slowing disease progression. Similarly, the anti-inflammatory and antioxidant properties of Giloy, including alkaloids, flavonoids, and polysaccharides, suggest its potential in mitigating neuroinflammation associated with PD.

Recent research has also explored the synergistic effects of combining these herbs with conventional treatments, showing improved outcomes in terms of motor function, neuroprotection, and overall quality of life for PD patients.

Reference:

1. Zahiruddin, S., Basist, P., Parveen, A., Parveen, R., Khan, W., & Ahmad, S. (2020). Ashwagandha in brain disorders: A review of recent developments. *Journal of Ethnopharmacology*, 257, 112876.
2. Singh, N., Bhalla, M., de Jager, P., & Gilca, M. (2011). An overview on Ashwagandha: A Rasayana (Rejuvenator) of Ayurveda. *African Journal of Traditional, Complementary and Alternative Medicines*, 8(5 SUPPL.), 208–213.

However, while these findings are encouraging, more rigorous

clinical trials and longitudinal studies are warranted to establish the safety and efficacy of Ashwagandha and Giloy as complementary or alternative therapeutic options for Parkinson's Disease.

In conclusion, the literature suggests that Ashwagandha and Giloy hold promise in the management of Parkinson's Disease, offering a natural and holistic approach to complement existing treatment strategies. Continued research and a deeper understanding of the molecular mechanisms underlying the therapeutic effects of these medicinal herbs are essential for their integration into mainstream Parkinson's Disease management protocols. As we advance in our understanding of the potential benefits of traditional herbal remedies, there exists a considerable opportunity to enhance the therapeutic armamentarium for Parkinson's Disease, providing patients with more diversified and personalized treatment options.

<https://doi.org/10.1016/j.jep.2020.112876>.

- <https://doi.org/10.4314/ajtcam.v8i5S.9>
3. Sharma, A., Bajaj, P., Bhandari, A., & Kaur, G. (2020). From ayurvedic folk medicine to preclinical neurotherapeutic role of a miraculous herb, *Tinospora cordifolia*. *Neurochemistry International*, 141, 104891. <https://doi.org/10.1016/J.NEUINT.2020.104891>
 4. Sharma, S. (2022). Role of *Withania somnifera* (Ashwagandha) in the Treatment of Neurological Disorders . *Current Nutrition & Food Science*, 19(2), 158–165. <https://doi.org/10.2174/157340131866220415084108>
 5. Singh, N., Bhalla, M., de Jager, P., & Gilca, M. (2011). An overview on Ashwagandha: A Rasayana (Rejuvenator) of Ayurveda. *African Journal of Traditional, Complementary and Alternative Medicines*, 8(5 SUPPL.), 208–213. <https://doi.org/10.4314/ajtcam.v8i5S.9>
 6. Bajaj, P., & Kaur, G. (2022). Acute Sleep Deprivation-Induced Anxiety and Disruption of Hypothalamic Cell Survival and Plasticity: A Mechanistic Study of Protection by Butanol Extract of *Tinospora cordifolia*. *Neurochemical Research*, 47(6), 1692–1706. <https://doi.org/10.1007/S11064-022-03562-8>
 7. Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. *The Lancet*, 397(10291), 2284–2303. [https://doi.org/10.1016/S0140-6736\(21\)00218-X](https://doi.org/10.1016/S0140-6736(21)00218-X)
 8. Collaborators, G. 2016 N. (2019). Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*, 18, 459–480.
 9. Dorsey, E., Sherer, T., Okun, M., & Bloem, B. (2018). The emerging evidence of the Parkinson pandemic. *J Parkinsons Dis*, 8, S3–S8.
 10. Kosaraju, J., Chinni, S., Roy, P. D., Kannan, E., Antony, A. S., & Kumar, M. N. S. (2014a). Neuroprotective effect of *Tinospora cordifolia* ethanol extract on 6-hydroxy dopamine induced Parkinsonism. *Indian Journal of Pharmacology*, 46(2), 176–180. <https://doi.org/10.4103/0253-7613.129312>
 11. Kosaraju, J., Chinni, S., Roy, P. D., Kannan, E., Antony, A. S., & Kumar, M. N. S. (2014b). Neuroprotective effect of *Tinospora cordifolia* ethanol extract on 6-hydroxy dopamine induced Parkinsonism. *Indian Journal of Pharmacology*, 46(2), 176–180. <https://doi.org/10.4103/0253-7613.129312>
 12. Pingali, U., Pilli, R., & Fatima, N. (2014). Effect of standardized aqueous extract of *Withania somnifera* on tests of cognitive and psychomotor performance in healthy

- human participants. *Pharmacognosy Research*, 6(1), 12–18.
<https://doi.org/10.4103/0974-8490.122912>
13. Skrahina, V., Gaber, H., Vollstedt, E. J., Förster, T. M., Usnich, T., Curado, F., Brüggemann, N., Paul, J., Bogdanovic, X., Zülbahar, S., Olmedillas, M., Skobalj, S., Ameziane, N., Bauer, P., Csoti, I., Koleva-Alazeh, N., Grittner, U., Westenberger, A., Kasten, M., ... Rolf, A. (2021). The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings. *Movement Disorders*, 36(4), 1005–1010.
<https://doi.org/10.1002/MDS.28416>
 14. Zahiruddin, S., Basist, P., Parveen, A., Parveen, R., Khan, W., Gaurav, & Ahmad, S. (2020). Ashwagandha in brain disorders: A review of recent developments. *Journal of Ethnopharmacology*, 257.
<https://doi.org/10.1016/J.JEP.2020.112876>
 15. Balkrishna, A., & Misra, L. (2018). Chemo-botanical and Neurological Accounts of Some Ayurvedic Plants Useful in Mental Health. *The Natural Products Journal*, 8(1), 14–31.
<https://doi.org/10.2174/2210315507666170616082903>
 16. Kulkarni, S. K., & Dhir, A. (2008). *Withania somnifera*: an Indian ginseng. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 32(5), 1093–1105.
<https://doi.org/10.1016/J.PNPBP.2007.09.011>
 17. Ven Murthy, M. R., K. Ranjekar, P., Ramassamy, C., & Deshpande, M. (2012). Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: 1. Ashwagandha. *Central Nervous System Agents in Medicinal Chemistry*, 10(3), 238–246.
<https://doi.org/10.2174/1871524911006030238>
 18. Mirjalili MH, Fakhr-Tabatabaei SM, Alizadeh H, Ghassempour A, Mirzajani F. Genetic and withaferin A analysis of Iranian natural populations of *Withania somnifera* and *W. coagulans* by RAPD and HPTLC. *Nat Prod Commun*. 2009 Mar;4(3):337-46. PMID: 19413110.
 19. Dar, N. J., & MuzamilAhmad. (2020). Neurodegenerative diseases and *Withania somnifera* (L.): An update. *Journal of Ethnopharmacology*, 256.
<https://doi.org/10.1016/J.JEP.2020.112769>
 20. Mukherjee, P. K., Banerjee, S., Biswas, S., Das, B., Kar, A., & Katiyar, C. K. (2021). *Withania somnifera* (L.) Dunal - Modern perspectives of an ancient Rasayana from Ayurveda. *Journal of Ethnopharmacology*, 264.
<https://doi.org/10.1016/j.jep.2020.113157>
 21. Kirson, I., and H. E. Gottlieb. "14 α -Hydroxy-steroids from *Withania somnifera* (L.) Dun.(Solanaceae)." *Journal of Ethnopharmacology*, 264.

- Journal Of Chemical Research-S 10 (1980): 338-339.
22. Tomar V, Beuerle T, Sircar D. A validated HPTLC method for the simultaneous quantifications of three phenolic acids and three withanolides from *Withania somnifera* plants and its herbal products. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2019 Aug 15;1124:154-160. doi: 10.1016/j.jchromb.2019.06.009. Epub 2019 Jun 6. PMID: 31200247.
 23. Schröter, H., Neumann, D., Katritzky, A., & Swinbourne, F. (1965). Withasomnine. A pyrazole alkaloid from *Withania somnifera* Dun. *Tetrahedron*, 22(8), 2895-2897. [https://doi.org/10.1016/S0040-4020\(01\)99082-9](https://doi.org/10.1016/S0040-4020(01)99082-9)
 24. Saleem, S., Muhammad, G., Hussain, M. A., Altaf, M., & Abbas Bukhari, S. N. (2020). *Withania somnifera* L.: Insights into the phytochemical profile, therapeutic potential, clinical trials, and future prospective. *Iranian Journal of Basic Medical Sciences*, 23(12), 1501-1526. <https://doi.org/10.22038/IJBMS.2020.44254.10378>
 25. Bessalle, R., & Lavie, D. (1992). Withanolide C, A chlorinated withanolide from *Withania somnifera*. *Phytochemistry*, 31(10), 3648-3651. [https://doi.org/10.1016/0031-9422\(92\)83749-O](https://doi.org/10.1016/0031-9422(92)83749-O)
 26. Anjaneyulu, A. S. R., and O. Satyanarayana Rao. "New withanolides from the roots of *Withania somnifera*." (1997).
 27. Tong X, Zhang H, Timmermann BN. Chlorinated Withanolides from *Withania somnifera*. *Phytochem Lett.* 2011 Dec;4(4):411-414. doi: 10.1016/j.phytol.2011.04.016. PMID: 22125584; PMCID: PMC3223914.
 28. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazón J. Steroidal lactones from *Withania somnifera*, an ancient plant for novel medicine. *Molecules.* 2009 Jul 3;14(7):2373-93. doi: 10.3390/molecules14072373. PMID: 19633611; PMCID: PMC6255378.
 29. Sharma, A., Bajaj, P., Bhandari, A., & Kaur, G. (2020). From ayurvedic folk medicine to preclinical neurotherapeutic role of a miraculous herb, *Tinospora cordifolia*. *Neurochemistry International*, 141, 104891. <https://doi.org/10.1016/j.neuint.2020.104891>
 30. Corso, C. D., & Bindra, R. S. (2016). Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. *Seminars in Radiation Oncology*, 26(4), 281-298. <https://doi.org/10.1016/j.semradonc.2016.06.003>
 31. Haque, M. A., Jantan, I., & Abbas Bukhari, S. N. (2017). *Tinospora* species: An overview of their modulating effects on the immune system. *Journal of Ethnopharmacology*, 207, 67-85. <https://doi.org/10.1016/j.jep.2017.06.013>
 32. Akhoun, B. A., Pandey, S., Tiwari, S., & Pandey, R. (2016). Withanolide A offers

- neuroprotection, ameliorates stress resistance and prolongs the life expectancy of *Caenorhabditis elegans*. *Experimental Gerontology*, 78, 47-56. <https://doi.org/10.1016/j.exger.2016.03.004>
33. Sharma, P., Dwivedee, B. P., Bisht, D., Dash, A. K., & Kumar, D. (2019). The chemical constituents and diverse pharmacological importance of *Tinospora cordifolia*. *Heliyon*, 5(9), e02437. <https://doi.org/10.1016/J.HELIYON.2019.E02437>
34. Singh, S., & Devi, P. (2017). ~ 1644 ~ *ZJournal of Pharmacognosy and Phytochemistry*, 6(6), 1644–1647.
35. *Phytochemicals in Giloy (Tinospora cordifolia L.): Structure, Chemistry, and Health Benefits | Request PDF*. (n.d.). Retrieved February 24, 2024, from https://www.researchgate.net/publication/339938834_Phytochemicals_in_Giloy_Tinospora_cordifolia_L_Structure_Chemistry_and_Health_Benefits
36. Balkrishna, A., Khandrika, L., & Varshney, A. (2021). Giloy Ghanvati (*Tinospora cordifolia* (Willd.) Hook. f. and Thomson) Reversed SARS-CoV-2 Viral Spike-Protein Induced Disease Phenotype in the Xenotransplant Model of Humanized Zebrafish. *Frontiers in Pharmacology*, 12, 635510. <https://doi.org/10.3389/FPHAR.2021.635510/BIBTEX>
37. Priyanka Sharma, Bharat P. Dwivedee, Dheeraj Bisht, Ashutosh K. Dash, Deepak Kumar, The chemical constituents and diverse pharmacological importance of *Tinospora cordifolia*, *Heliyon*, <https://doi.org/10.1016/j.heliyon.2019.e02437>.